GE Healthcare Awarded Contract to Design New Plant-Based Biopharmaceutical Facility in Brazil
New facility for Bio-Manguinhos will use plant-based protein expression technology.
GE Healthcare and iBio Inc. have signed a contract under which GE Healthcare will design a new plant-based multipurpose manufacturing facility for Bio-Manguinhos/Fiocruz in Brazil. The design project is the first contract for the global alliance between GE Healthcare and iBio, which was announced in 2012.
The alliance combines iBio’s plant-based manufacturing platform, iBioLaunch with GE Healthcare’s capabilities in process design and biopharmaceutical and vaccine manufacturing technologies. Bio-Manguinhos/Fiocruz is a manufacturer of immunobiologicals for public health needs, primarily to support programs of the Brazilian Ministry of Health. It has invested in the development of bioprocess technologies, such as iBioLaunch, through a codevelopment agreement with iBio and its research and development collaborator the Fraunhofer USA Center for Molecular Biotechnology, which will continue to play a role in advancing iBioLaunch. The iBioLaunch platform is a proprietary technology for the development and production of biologics using transient gene expression in unmodified green plants.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
